(Prostate cancer vaccine(Onyvax Ltd.)) - 在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名

ONY-P、Onyvax-P、Prostate cancer vaccine

+ [2]

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

Onyvax Ltd.

在研机构

Onyvax Ltd.

National Cancer Institute

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

4

项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床试验

EUCTR2006-001619-31-HU / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2008-03-21

申办/合作机构

Onyvax Ltd.

EUCTR2006-001619-31-EE / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2006-10-16

申办/合作机构

Onyvax Ltd.

EUCTR2006-001619-31-LT / Not yet recruitingN/A

A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES

开始日期2006-07-17

申办/合作机构

Onyvax Ltd.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的专利（医药）

登录后查看更多信息

3

项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的文献（医药）

2005-10-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-P, Onyvax.

Review

作者: Böhmer, Torsten ; Doehn, Christian ; Jocham, Dieter

Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.

2003-12-01·Current opinion in molecular therapeutics

Technology evaluation: Onyvax-105, Onyvax.

Article

作者: Blumenthal, Rosalyn D

Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000.

1985-03-01·Journal of the American Academy of Dermatology1区 · 医学

Onycholysis of the fingernails: Evaluation and management

1区 · 医学

Review

作者: Paul Kechijian

Onycholysis (ONY) of the fingernails is a common disorder that is diagnosed with ease but often managed with great difficulty. The full spectrum of causes is broad and not always readily apparent. In this review, an approach to the evaluation and management of ONY is offered.

100 项与 Prostate cancer vaccine(Onyvax Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前列腺癌	临床2期	-	Onyvax Ltd.	-
前列腺癌	临床2期	-	National Cancer Institute	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2005	临床2期	前列腺癌转移	20	ONY-P1	觸鬱獵觸膚顧鑰衊鹹構(鏇鑰艱觸選繭壓範鬱觸) = A statistically significant sustained PSA velocity reduction was seen in 3 patients (23%) 鹹繭壓蓋範構糧製鏇衊 (遞齋夢衊齋蓋鏇膚窪憲 )	-	2005-06-01